Novartis has acknowledged that its neuromuscular candidate delpacibart etedesiran (del-desiran) failed a pivotal Phase III ...

Researchers hope that the study could lead to new osteoporosis treatments that tackle bone loss and address some of the wider ...

The funds will support efforts to advance its lead candidate into human clinical trials in 2027, and expand its pipeline of ...

Researchers show mutant NRAS and wild-type HRAS cooperate in cancer signaling, pointing to mutation-guided combination ...

Transgene, based in France, is focused on the design and development of immunotherapies for the treatment of cancer.

A secured bioinformatics backbone, the most critical part of next-generation sequencing, means reliable, auditable data handling.

RNAV8 will be part of a team led by the Rouskin Lab at Harvard Medical School with the Weissman Lab at MIT/the Whitehead ...

BrainChild Bio has raised a $116 million Series A financing, the proceeds of which will, in part, fund the pivotal ...

The DARPA project had the potential to improve athletic performance and help treat conditions involving a lack of oxygen in ...

Gene therapy will not reach its full potential as a transformative treatment for genetic diseases unless manufacturing ...

Preclinical findings are the basis for an upcoming Phase II clinical trial evaluating psilocybin during chemotherapy in ...

Venetoclax, a cancer drug that inhibits BCL-2, reduced the intact SIV reservoir in macaques and may inform future HIV cure ...